More HER2-discordant patients were found in ER-negative and TNBC tumors after adjusting for clinicopathological parameters, indicating the possible crucial role of the ER signaling pathway in influencing HER2-Low breast cancer [35,36,37]. The gene discussed is ERBB2; the disease is breast carcinoma.